文献速递脑血管病

基线ASPECTS对替奈普酶在取栓前疗效的影响:BRIDGE-TNK随机试验事后分析

Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial.
PubMed 文献 · Neurology · 2026-08-20

该研究为BRIDGE-TNK试验事后分析,纳入550例前循环大血管闭塞卒中患者,按基线ASPECTS分为<8和8-10两组,比较替奈普酶联合取栓与单纯取栓的疗效与安全性。结果显示ASPECTS<8组联合治疗功能独立率显著更高(aRR 1.67),而ASPECTS 8-10组无显著获益且死亡率数值更高。

要点

  • ASPECTS<8患者接受替奈普酶联合取栓功能独立率显著高于单纯取栓。
  • ASPECTS 8-10患者联合治疗无功能获益,且90天死亡率数值更高。
  • 需前瞻性随机试验确认后方可改变临床实践。

核心结论

  • 在ASPECTS<8患者中观察到替奈普酶联合取栓的获益信号,而ASPECTS 8-10患者无功能改善且可能存在安全性顾虑。

研究设计与样本

  • BRIDGE-TNK随机试验的事后分析,2022年5月至2024年9月在中国开展,纳入550例发病4.5小时内急性大血管闭塞卒中患者,按基线ASPECTS<8与8-10分层比较替奈普酶联合取栓与单纯取栓。

主要发现

  • ASPECTS<8亚组联合治疗组功能独立率显著高于单纯取栓组(aRR 1.67;95%CI 1.18-2.35),ASPECTS 8-10亚组无显著差异(aRR 0.99;95%CI 0.84-1.17;交互P=0.007)。
  • 症状性颅内出血率在两亚组治疗间均无显著差异(ASPECTS<8:10.0% vs 11.2%;ASPECTS 8-10:7.5% vs 2.8%;交互P=0.11)。
  • 90天死亡率在ASPECTS<8亚组两组相当,但在ASPECTS 8-10亚组联合治疗组数值更高(aRR 1.89,95%CI 0.99-3.61,交互P=0.04)。

关键数值与推荐

  • ASPECTS<8亚组功能独立aRR 1.67(95%CI 1.18-2.35)。
  • ASPECTS 8-10亚组功能独立aRR 0.99(95%CI 0.84-1.17),交互P=0.007。
  • ASPECTS 8-10亚组90天死亡率aRR 1.89(95%CI 0.99-3.61),交互P=0.04。

临床怎么用

  • 对于ASPECTS<8的前循环大血管闭塞患者,取栓前静脉替奈普酶可能改善功能预后;ASPECTS 8-10患者应谨慎权衡获益与潜在死亡风险,目前尚不能据此改变实践。

局限性

  • 为探索性事后分析,需前瞻性随机试验确认后方可改变临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The impact of ischemic extent on the efficacy and safety of intravenous thrombolysis before thrombectomy remains uncertain. The aim of this study was to evaluate whether the baseline ischemic extent, measured by the Alberta Stroke Program Early Computed Tomography Score (ASPECTS), modifies outcomes of intravenous tenecteplase administered before endovascular thrombectomy. METHODS: This was a post hoc analysis of the BRIDGE-TNK (thrombectomy with vs without rhTNK-tPA in stroke) trial, conducted across China from May 2022 to September 2024. We compared the efficacy and safety of intravenous tenecteplase plus thrombectomy vs thrombectomy alone in acute large-vessel occlusion stroke patients within 4.5 hours of last known well, stratified by baseline ASPECTS (<8 vs 8-10). The outcomes included 90-day functional independence (modified Rankin Scale score of 0-2), 48-hour symptomatic intracranial hemorrhage (sICH), and 90-day mortality. Regression models incorporating a treatment-by-ASPECTS interaction term were used for analysis. RESULTS: Among 550 patients, 241 (43.8%) had ASPECTS <8 (median [interquartile range, IQR] age, 69 [61-77] years; 56.4% male) and 309 had ASPECTS 8-10 (median [IQR] age, 70 [61-77] years; 59.5% male). The rate of functional independence was significantly higher in the tenecteplase plus thrombectomy group than in the thrombectomy-alone group in the ASPECTS <8 subgroup (adjusted risk ratio [aRR], 1.67; 95% CI 1.18-2.35), but not in the ASPECTS 8-10 subgroup (aRR, 0.99; 95% CI 0.84-1.17; pinteraction = 0.007). Rates of sICH did not differ significantly between treatment groups in either ASPECTS subgroups (ASPECTS <8: 10.0% vs 11.2%; ASPECTS 8-10: 7.5% vs 2.8%; pinteraction = 0.11). Ninety-day mortality was comparable between treatment groups in the ASPECTS <8 subgroup, but numerically higher with tenecteplase plus thrombectomy in the ASPECTS 8-10 subgroup (aRR = 1.89, 95% CI 0.99-3.61, pinteraction = 0.04). DISCUSSION: In this exploratory post hoc analysis, a signal of benefit was observed in patients with ASPECTS <8 who received intravenous tenecteplase before thrombectomy, whereas no functional improvement and possible safety concerns were seen in those with ASPECTS 8-10. Prospective confirmation in randomized trials is required before practice change. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov; Unique identifier: NCT04733742.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Huang X, Xu J, Saver JL, et al. Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial. Neurology. 2026. PMID: 42623571. doi:10.1212/WNL.0000000000218467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。